The authors recommended that melanomas that originate on mucosal, acral, or chronic sun damage (CSD) skin should be investigated for KIT mutations and that imatinib is beneficial when tumors harbor KIT mutations, while it is ineffective when KIT is only amplified. Here, KIT is linked to melanoma.